Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 4/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15009045 | 1.00 | KCNH2 (0.41) | KCNH2VNN1RORCFGFR4SLC6A9 | |
| SCHEMBL15008820 | 0.93 | KCNH2 (0.40) | KCNH2VNN1RORCPTK2CCNE1 | |
| SCHEMBL15024818 | 0.93 | KCNH2 (0.40) | KCNH2VNN1RORCPTK2CCNE1 | |
| SCHEMBL2576898 | 0.93 | KCNH2 (0.37) | KCNH2VNN1RORCSLC6A9 | |
| SCHEMBL2576904 | 0.93 | KCNH2 (0.37) | KCNH2VNN1RORCSLC6A9 | |
| SCHEMBL15024785 | 0.93 | KCNH2 (0.34) | KCNH2VNN1RORCFGFR4SLC6A9 | |
| SCHEMBL15009359 | 0.93 | KCNH2 (0.34) | KCNH2VNN1RORCFGFR4SLC6A9 | |
| SCHEMBL15024714 | 0.92 | KCNH2 (0.35) | KCNH2VNN1RORCSLC6A9PDE4B | |
| SCHEMBL2574547 | 0.91 | KDR (0.36) | KCNH2VNN1RORCSLC6A9PDE4B | |
| SCHEMBL12293921 | 0.91 | KDR (0.36) | KCNH2VNN1RORCSLC6A9PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994528-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994528-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | disclosed |
| EP-2560488-B1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, PRMT5, H1-5 | KCNH2 463/4885VNN1 4156/4885RORC 530/4885 |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, PRMT5, H1-5 | KCNH2 463/4885VNN1 4156/4885RORC 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.